• Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization 

      Zheng, Jie; Wheeler, Eleanor; Pietzner, Maik; Andlauer, Till F.M.; Yau, Michelle S.; Hartley, April E.; Brumpton, Ben Michael; Rasheed, Humaira; Kemp, John P.; Frysz, Monika; Robinson, Jamie; Reppe, Sjur; Prijatelj, Vid; Gautvik, Kaare M; Falk, Louise; Maerz, Winfried; Gergei, Ingrid; Peyser, Patricia A; Kavousi, Maryam; de Vries, Paul S.; Miller, Clint L.; Bos, Maxime; Van Der Laan, Sander W.; Malhotra, Rajeev; Herrmann, Markus; Scharnagl, Hubert; Kleber, Marcus; Dedoussis, George; Zeggini, Eleftheria; Nethander, Maria; Ohlsson, Claes; Lorentzon, Mattias; Wareham, Nick; Langenberg, Claudia; Holmes, Michael V.; Smith, George Davey; Tobias, Jonathan H. (Peer reviewed; Journal article, 2023)
      Objective In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. Methods A genome-wide association ...